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Clinical PerspectiveWhat Is New?This study shows that the obesity paradox persists in contemporary percutaneous coronary intervention practice, whereby overweight and obese patients have better post--percutaneous coronary intervention long‐term survival than those with normal body mass index.However, our study demonstrates that this protective effect does not extend to patients with extreme obesity.What Are the Clinical Implications?Our study demonstrates that there is a threshold effect to the obesity paradox, which is important for clinicians to recognize when risk‐stratifying patients.We also show that patients with normal body mass index are less likely to receive appropriate secondary prevention therapy compared with their higher body mass index counterparts.More attention needs to be paid to reducing this treatment gap in clinical practice, which may help improve outcomes in patients with normal body mass index.

Introduction {#jah34464-sec-0008}
============

Obesity is a growing health concern worldwide, particularly in developed countries, where there has been an unprecedented rise in the proportion of overweight and obese individuals in the population.[1](#jah34464-bib-0001){ref-type="ref"}, [2](#jah34464-bib-0002){ref-type="ref"} Obesity is associated with numerous adverse health outcomes including coronary artery disease, stroke, heart failure, and diabetes mellitus and has also been linked to higher rates of mortality.[3](#jah34464-bib-0003){ref-type="ref"}, [4](#jah34464-bib-0004){ref-type="ref"} Despite this, several studies in the past have described an "obesity paradox" whereby obesity appears to confer a protective effect compared with normal body mass index (BMI), in a variety of medical conditions.[5](#jah34464-bib-0005){ref-type="ref"}, [6](#jah34464-bib-0006){ref-type="ref"}, [7](#jah34464-bib-0007){ref-type="ref"}, [8](#jah34464-bib-0008){ref-type="ref"}, [9](#jah34464-bib-0009){ref-type="ref"} This was also described in the setting of percutaneous coronary intervention (PCI), where overweight and obese patients were shown to have lower rates of short‐term mortality compared with normal‐BMI individuals.[10](#jah34464-bib-0010){ref-type="ref"}, [11](#jah34464-bib-0011){ref-type="ref"}, [12](#jah34464-bib-0012){ref-type="ref"} A meta‐analysis of over 200 000 patients with myocardial infarction also reported that obese patients have a 30% to 40% lower mortality compared with individuals with normal BMI over a 1‐ to 3‐year follow‐up period.[13](#jah34464-bib-0013){ref-type="ref"} However, more recent studies in patients in the contemporary era of PCI have produced conflicting results.[14](#jah34464-bib-0014){ref-type="ref"}, [15](#jah34464-bib-0015){ref-type="ref"}, [16](#jah34464-bib-0016){ref-type="ref"}, [17](#jah34464-bib-0017){ref-type="ref"}, [18](#jah34464-bib-0018){ref-type="ref"} In particular, despite extreme obesity (BMI≥40 kg/m^2^) increasing in prevalence among patients undergoing PCI, few studies have examined long‐term clinical outcomes in this group.[19](#jah34464-bib-0019){ref-type="ref"}, [20](#jah34464-bib-0020){ref-type="ref"} Studies examining in‐hospital mortality of patients undergoing PCI have suggested that although lesser degrees of obesity may be protective, this effect does not extend to patients with extreme obesity.[12](#jah34464-bib-0012){ref-type="ref"}, [19](#jah34464-bib-0019){ref-type="ref"} However, very few earlier studies have assessed mortality rates beyond 12 months in patients with extreme obesity undergoing PCI for both stable angina and acute coronary syndromes.

In this study we therefore sought to determine whether an obesity paradox persists in contemporary PCI practice over long‐term follow‐up and, in particular, to further evaluate the association between extreme obesity and long‐term clinical outcomes after PCI.

Methods {#jah34464-sec-0009}
=======

Due to the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to Ms Angela Brennan of Monash University at <angela.brennan@monash.edu>.

This was a cohort study of patients undergoing PCI between January 1, 2005 and June 30, 2017 inclusive, enrolled prospectively in the MIG (Melbourne Interventional Group) registry. All consecutive adult patients undergoing PCI were eligible for inclusion. We excluded patients in whom height and/or weight was not recorded at the time of PCI, and therefore BMI could not be calculated. Patients who could not be considered for linkage to the Australian NDI (National Death Index) mortality database due to incomplete case information at the time the registry data were sent for linkage were also excluded (n=267).

For all patients included in this study, BMI was calculated by dividing weight (in kilograms) by the square of the height (in meters). Patients were classified into the following 6 groups by their BMI as per the World Health Organization Classification System: underweight (BMI\<18.5 kg/m^2^), normal weight (BMI 18.5‐24.9 kg/m^2^), overweight (BMI 25‐29.9 kg/m^2^), class I obese (BMI 30‐34.9 kg/m^2^), class II obese (BMI 35‐39.9 kg/m^2^), and class III obese (BMI≥40 kg/m^2^).[21](#jah34464-bib-0021){ref-type="ref"} However, due to the very small sample size in the underweight group (n=232), which is likely to make comparisons with the other groups imprecise, these patients were excluded in deriving our final study cohort.

The MIG registry is a multicenter Australian PCI registry that collects data from 6 participating hospitals, 4 of which are located in metropolitan Melbourne, and 2 hospitals are located in large regional centers.[22](#jah34464-bib-0022){ref-type="ref"} Baseline demographic, clinical, procedural, and in‐hospital outcome data are prospectively recorded on case‐report forms using standardized definitions for all fields (Table [S1](#jah34464-sup-0001){ref-type="supplementary-material"}). Relevant information for 30‐day outcomes was obtained through telephone follow‐up with further review of medical records performed in patients who reported any events.[23](#jah34464-bib-0023){ref-type="ref"} In addition, mortality data were obtained by linkage to the Australian NDI, a database housed at the Australian Institute of Health and Welfare that contains records of all deaths occurring in Australia since 1980. The censoring date for linkage with the NDI in this study was August 1, 2017. Successful matching of patients through this linkage process was achieved in 99.0% of all patients in the study cohort. The MIG registry has an "opt‐out" consent process as previously described and has been granted ethics approval by the ethics committee at The Alfred Hospital (approval number 92/04) as well as by committees at each participating hospital.[22](#jah34464-bib-0022){ref-type="ref"}, [23](#jah34464-bib-0023){ref-type="ref"}

Baseline and procedural characteristics, as well as in‐hospital and 30‐day outcomes, were compared among the groups. The primary end point was NDI‐linked long‐term mortality. Secondary end points included death (all‐cause mortality and cardiac mortality), myocardial infarction, target vessel revascularization and major adverse cardiovascular events at 30‐day follow‐up. Major adverse cardiovascular events were defined as a composite of death, myocardial infarction, and target vessel revascularization. Major bleeding was defined as a fall in hemoglobin by \>3.0 g/dL and/or requiring transfusion. Use of antiplatelet therapy, β‐blockers, angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, and cholesterol‐lowering therapies (statins, fibrates, and ezetimibe) at 30 days after the index PCI was also compared among the groups. Prescription of postdischarge medications was at the discretion of the treating physician according to contemporary guidelines.

Continuous variables are expressed as mean±SD and were compared using a Kruskal‐Wallis equality‐of‐populations rank test. Categorical data are expressed as numbers and percentages and compared using the Pearson chi‐squared test or Fisher exact test as appropriate. The Kaplan‐Meier method was used to estimate post‐PCI survival rates, and the log‐rank test was used for survival comparisons. Cox proportional hazard modeling was used to identify independent predictors of the primary end point of NDI‐linked long‐term mortality. In this model in addition to BMI group, 28 other clinically relevant variables such as sex, cardiovascular risk factors including diabetes mellitus, hypertension, and renal impairment, history of previous myocardial infarction and/or previous stroke, disease extent on angiography, and type of stent used were considered. Aside from the BMI group, only variables with a *P*\<0.10 on univariate analysis that were not collinear were entered into a stepwise backward selection modeling process for multivariable assessment. Complete case analysis was performed for purposes of multivariable modeling (ie, patients with missing values were excluded). The proportion of missing variables was \<1% for all variables except smoking status (1.6%), estimated glomerular filtration rate (3.9%), family history of coronary artery disease (4.5%), 30‐day medications (7.3%), and left ventricular ejection fraction (11.7%).

All statistical analyses were performed using Stata 13.1 software (StataCorp LP, College Station, TX). *P*\<0.05 was considered to be statistically significant.

Results {#jah34464-sec-0010}
=======

In total, 25 413 patients were included in this analysis. Of these, 6305 (24.6%) were in the normal BMI category, 10 608 (41.4%) were overweight, 5780 (22.5%) had mild (class I) obesity, 1874 (7.3%) had moderate (class II) obesity, and 846 (3.3%) had extreme (class III) obesity. The mean age of the whole study cohort was 64.2±12.0 years, and 23.0% were female.

Baseline Characteristics {#jah34464-sec-0011}
------------------------

Table [1](#jah34464-tbl-0001){ref-type="table"} shows the baseline characteristics of the study cohort stratified by BMI groups. With increasing BMI, patients were younger and had more cardiovascular risk factors such as diabetes mellitus (all *P*\<0.001). The proportion of women was highest at both extremes of BMI and lowest in the overweight group. With increasing BMI, the proportion of patients who presented with non--ST‐elevation acute coronary syndromes increased, whereas the proportion of patients who presented with ST‐elevation myocardial infarction, out‐of‐hospital cardiac arrest, and cardiogenic shock decreased (*P*≤0.001).

###### 

Baseline Characteristics

                                                  BMI 18.5 to 24.9 kg/m^2^   BMI 25.0 to 29.9 kg/m^2^   BMI 30.0 to 34.9 kg/m^2^   BMI 35.0 to 39.9 kg/m^2^   BMI ≥40 kg/m^2^   *P* for Trend
  ----------------------------------------------- -------------------------- -------------------------- -------------------------- -------------------------- ----------------- ---------------
  N (%)                                           6305 (24.6)                10 608 (41.4)              5780 (22.5)                1874 (7.3)                 846 (3.3)         
  Mean age±SD, y                                  67.0±12.4                  64.4±11.8                  62.7±11.6                  61.0±10.7                  59.2±10.7         \<0.001
  Age \>80 years                                  966 (15.3)                 944 (8.9)                  340 (5.9)                  56 (3.0)                   19 (2.3)          \<0.001
  Female                                          1664 (26.4)                1967 (18.5)                1281 (22.2)                586 (31.3)                 354 (41.8)        \<0.001
  Diabetes mellitus                               1022 (16.2)                2419 (22.8)                1735 (30.0)                784 (41.8)                 381 (45.0)        \<0.001
  Hypertension                                    3731 (59.2)                6848 (64.6)                4233 (73.3)                1475 (78.8)                675 (79.8)        \<0.001
  Dyslipidemia                                    3836 (61.0)                7081 (66.9)                4140 (71.6)                1385 (74.0)                611 (72.4)        \<0.001
  Current or past smoker                          4016 (64.7)                6975 (66.7)                4001 (70.5)                1262 (68.4)                585 (70.1)        \<0.001
  Family history of coronary artery disease       2096 (34.7)                3939 (38.9)                2236 (40.6)                726 (40.7)                 370 (46.1)        \<0.001
  eGFR \>60 mL/min per 1.73 m^2^                  4594 (75.9)                8019 (79.0)                4346 (77.7)                1400 (77.7)                602 (74.1)        0.694
  eGFR 30 to 60 mL/min per 1.73 m^2^              1242 (20.5)                1864 (18.4)                1108 (19.8)                355 (19.7)                 181 (22.3)        
  eGFR \<30 mL/min per 1.73 m^2^                  216 (3.6)                  262 (2.6)                  143 (2.6)                  48 (2.7)                   30 (3.7)          
  Chronic obstructive pulmonary disease           505 (8.0)                  545 (5.1)                  341 (5.9)                  109 (5.8)                  53 (6.3)          \<0.001
  Obstructive sleep apnea                         98 (1.6)                   305 (2.9)                  366 (6.3)                  245 (13.1)                 175 (20.7)        \<0.001
  Peripheral vascular disease                     439 (7.0)                  547 (5.2)                  347 (6.0)                  109 (5.8)                  36 (4.3)          0.007
  Previous stroke                                 427 (6.8)                  547 (5.2)                  320 (5.5)                  108 (5.8)                  51 (6.0)          0.072
  Previous myocardial infarction                  1563 (24.8)                2717 (25.6)                1600 (27.7)                535 (28.6)                 236 (28.0)        \<0.001
  Previous percutaneous coronary intervention     1543 (24.5)                2734 (25.8)                1610 (27.9)                533 (28.4)                 227 (26.8)        \<0.001
  Previous coronary artery bypass graft surgery   457 (7.3)                  880 (8.3)                  488 (8.4)                  179 (9.6)                  49 (5.8)          0.107
  Clinical presentation                                                                                                                                                         
  Stable angina                                   1832 (29.1)                3597 (33.9)                2075 (35.9)                708 (37.8)                 264 (31.2)        \<0.001
  Unstable angina                                 513 (8.1)                  870 (8.2)                  448 (7.8)                  163 (8.7)                  66 (7.8)          0.856
  NSTEMI                                          1778 (28.2)                2821 (26.6)                1700 (29.4)                569 (30.4)                 291 (34.4)        \<0.001
  STEMI                                           2180 (34.6)                3318 (31.3)                1554 (26.9)                434 (23.2)                 224 (26.5)        \<0.001
  Cardiogenic shock                               257 (4.1)                  286 (2.7)                  145 (2.5)                  32 (1.7)                   21 (2.5)          \<0.001
  Out‐of‐hospital cardiac arrest                  200 (3.2)                  315 (3.0)                  148 (2.6)                  38 (2.0)                   18 (2.1)          0.001
  Mean LV ejection fraction±SD                    52.2±11.0                  52.8±10.4                  53.2±9.9                   53.4±9.8                   53.5±9.9          \<0.001
  LV ejection fraction \<30%                      130 (2.3)                  157 (1.7)                  62 (1.2)                   22 (1.4)                   8 (1.1)           \<0.001
  LV ejection fraction 30% to 45%                 1295 (2.3)                 157 (1.7)                  62 (1.2)                   22 (1.4)                   8 (1.1)           
  LV ejection fraction \>45%                      4236 (74.8)                7318 (77.8)                4001 (79.5)                1289 (80.9)                598 (81.7)        

Data expressed as mean±SD or numbers (%).BMI indicates body mass index; eGFR, estimated glomerular filtration rate; LV, left ventricular; NSTEMI, non--ST‐elevation myocardial infarction; STEMI, ST‐elevation myocardial infarction.

Procedual characteristics are shown in Table [2](#jah34464-tbl-0002){ref-type="table"}. As BMI increased, there was more radial access and less femoral access use (*P*\<0.001). There were no significant differences in extent of coronary artery disease or lesion complexity by BMI group. Drug‐eluting stents were more frequently implanted in the higher BMI groups (*P*\<0.001). Procedural complications such as coronary dissection and perforation were overall infrequent, but less common in the higher BMI groups (both *P*\<0.04), although the overall proportion of unsuccessful PCIs was similar across the BMI groups (*P*=0.440). There was also a reduction in the proportion of patients with severe left ventricular systolic dysfunction (left ventricular ejection fraction \<30%) at the time of PCI, with increasing BMI (*P*\<0.001).

###### 

Procedural Characteristics

                                        BMI 18.5 to 24.9 kg/m^2^   BMI 25.0 to 29.9 kg/m^2^   BMI 30.0 to 34.9 kg/m^2^   BMI 35.0 to 39.9 kg/m^2^   BMI ≥40 kg/m^2^   *P* for Trend
  ------------------------------------- -------------------------- -------------------------- -------------------------- -------------------------- ----------------- ---------------
  Lesion characteristics                                                                                                                                              
  Multivessel disease                   3712 (59.0)                6248 (59.0)                3383 (58.6)                1085 (58.1)                461 (54.6)        0.054
  Left main lesion                      89 (1.2)                   135 (1.1)                  76 (1.1)                   22 (1.0)                   7 (0.7)           0.243
  Chronic total occlusion lesion        229 (3.1)                  480 (3.8)                  269 (4.0)                  98 (4.5)                   37 (3.7)          0.003
  ACC/AHA type B2/C lesion              4221 (56.2)                7075 (56.2)                3804 (56.1)                1304 (59.2)                566 (56.3)        0.206
  Procedural details                                                                                                                                                  
  Radial access                         1434 (22.7)                2675 (25.2)                1594 (27.6)                549 (29.3)                 290 (34.3)        \<0.001
  Femoral access                        4871 (77.3)                7932 (74.8)                4186 (72.4)                1325 (70.7)                556 (65.7)        
  Arterial access closure device used   645 (10.2)                 1123 (10.6)                587 (10.2)                 223 (11.9)                 121 (14.3)        0.004
  Balloon angioplasty only              411 (6.5)                  657 (6.2)                  410 (7.1)                  130 (6.9)                  56 (6.6)          0.001
  Bare metal stent                      2471 (39.2)                4035 (38.0)                2089 (36.1)                628 (33.5)                 308 (36.4)        
  Drug‐eluting stent                    3423 (54.3)                5916 (55.8)                3281 (56.8))               1116 (59.6)                482 (57.0)        
  Intra‐aortic balloon pump use         136 (2.2)                  177 (1.7)                  82 (1.4)                   17 (0.9)                   9 (1.1)           \<0.001
  Thrombectomy device used              520 (8.0)                  884 (8.0)                  406 (6.8)                  105 (5.4)                  49 (5.4)          \<0.001
  Glycoprotein IIb/IIIa inhibitors      1854 (29.4)                2991 (28.2)                1441 (25.0)                431 (23.0)                 197 (23.3)        \<0.001
  Complications                                                                                                                                                       
  Dissection                            339 (4.5)                  533 (4.2)                  265 (3.9)                  84 (3.8)                   32 (3.2)          0.004
  Perforation                           24 (0.3)                   39 (0.3)                   12 (0.2)                   5 (0.2)                    0 (0.0)           0.011
  Transient/persistent no‐reflow        280 (3.9)                  350 (2.9)                  200 (3.1)                  58 (2.7)                   32 (3.3)          0.019
  Unsuccessful PCI                      334 (5.3)                  514 (4.9)                  310 (5.4)                  102 (5.4)                  48 (5.7)          0.440

Data expressed as mean±SD, or numbers (%).ACC/AHA indicates American College of Cardiology/American Heart Association; BMI, body mass index; PCI, percutaneous coronary intervention.

Clinical Outcomes {#jah34464-sec-0012}
-----------------

In‐hospital and 30‐day outcomes are shown in Table [3](#jah34464-tbl-0003){ref-type="table"}. A 30‐day follow‐up was completed in 99.6% of the study cohort. There was a J‐shaped association between BMI and both in‐hospital and 30‐day mortality, with a steady fall in mortality from the normal BMI group to the moderate obesity group, followed by a substantial rise in mortality in the extreme obesity group (*P*\<0.001). A similar pattern of association was also seen with in‐hospital and 30‐day major adverse cardiovascular events. With increasing BMI, there was a significant stepwise reduction in in‐hospital bleeding (*P*\<0.001). There were no significant differences in 30‐day readmission rates across the BMI groups.

###### 

Clinical Outcomes

                                         BMI 18.5 to 24.9 kg/m^2^   BMI 25.0 to 29.9 kg/m^2^   BMI 30.0 to 34.9 kg/m^2^   BMI 35.0 to 39.9 kg/m^2^   BMI ≥40 kg/m^2^   *P* for Trend
  -------------------------------------- -------------------------- -------------------------- -------------------------- -------------------------- ----------------- ---------------
  In‐hospital outcomes                                                                                                                                                 
  Death                                  142 (2.3)                  175 (1.6)                  74 (1.3)                   20 (1.1)                   16 (1.9)          \<0.001
  Cardiac death                          113 (1.8)                  144 (1.4)                  58 (1.0)                   18 (1.0)                   11 (1.3)          0.799
  Periprocedural myocardial infarction   76 (1.2)                   113 (1.1)                  60 (1.0)                   20 (1.1)                   6 (0.7)           0.208
  Heart failure                          263 (4.2)                  357 (3.4)                  188 (3.3)                  52 (2.8)                   38 (4.5)          0.041
  Acute kidney injury                    111 (1.8)                  191 (1.8)                  87 (1.5)                   21 (1.1)                   23 (2.7)          0.591
  Major bleeding                         208 (3.3)                  196 (1.9)                  107 (1.9)                  24 (1.3)                   10 (1.2)          \<0.001
  Stroke                                 24 (0.4)                   22 (0.2)                   22 (0.4)                   4 (0.2)                    1 (0.1)           0.380
  Target vessel revascularization        77 (1.2)                   115 (1.1)                  69 (1.2)                   19 (1.0)                   11 (1.3)          0.931
  MACE                                   265 (4.2)                  374 (3.5)                  181 (3.1)                  58 (3.1)                   31 (3.7)          0.007
  30‐day outcomes                                                                                                                                                      
  Death                                  177 (2.8)                  211 (2.0)                  95 (1.7)                   24 (1.3)                   21 (2.5)          \<0.001
  Cardiac death                          133 (2.1)                  161 (1.5)                  71 (1.2)                   21 (1.1)                   13 (1.5)          0.774
  Myocardial infarction                  129 (2.1)                  175 (1.7)                  104 (1.8)                  30 (1.6)                   8 (1.0)           0.045
  Stroke                                 38 (0.6)                   33 (0.3)                   25 (0.4)                   8 (0.4)                    1 (0.1)           0.084
  Target vessel revascularization        146 (2.3)                  234 (2.2)                  133 (2.3)                  52 (2.8)                   20 (2.4)          0.452
  Any readmission                        751 (12.3)                 1084 (10.5)                653 (11.6)                 219 (12.0)                 93 (11.3)         0.610
  MACE                                   375 (6.0)                  527 (5.0)                  276 (4.8)                  88 (4.7)                   42 (5.0)          0.008
  NDI‐linked mortality                                                                                                                                                 
  No. of deaths                          1195 (19.2)                1423 (13.5)                751 (13.1)                 225 (12.2)                 118 (14.1)        \<0.001
  Median follow‐up time (IQR), y         4.4 (2.0‐7.5)              4.5 (2.0‐7.7)              4.4 (2.0‐7.6)              4.1 (2.0‐7.0)              3.9 (1.5‐6.9)     0.047

Data expressed as median (IQR) or numbers (%). BMI indicates body mass index; IQR, interquartile range; MACE, major adverse cardiovascular events; NDI, national death index.

All‐cause mortality data beyond 30 days were obtained using linkage with the NDI database. Median length of follow‐up was 4.4 years (IQR 2.0‐7.6 years) overall and similar in all the groups (*P*=0.047). Patients with moderate obesity had the lowest mortality rate (12.2%), whereas patients both with normal BMI and extreme obesity were found to have a higher mortality rate (19.2% and 14.1% respectively). The Kaplan‐Meier survival curves for the 5 BMI groups are shown in Figure [1](#jah34464-fig-0001){ref-type="fig"}, and they confirm that patients with extreme obesity had significantly lower long‐term survival, compared to the other groups (log rank *P*\<0.001). Using Cox‐proportional hazards modelling with the normal BMI group as the reference category, a J‐shaped association between BMI and adjusted hazard ratio for NDI‐linked long‐term mortality was observed (Figure [2](#jah34464-fig-0002){ref-type="fig"}). The adjusted hazard ratio (HR) was highest for patients with extreme obesity (HR 1.33, 95% CI 1.07‐1.65). Being overweight and having mild obesity both appeared to be protective for long‐term NDI‐linked mortality, with the latter group having the lowest adjusted hazard ratio. The 3 strongest independent predictors of NDI‐linked long‐term mortality were stage 4 to 5 chronic kidney disease, cardiogenic shock, and severe left ventricular systolic dysfunction (HR 3.46, 2.98 and 2.50 respectively; all *P*\<0.001) (Table [4](#jah34464-tbl-0004){ref-type="table"}).

![Kaplan‐Meier curves of long‐term survival by body mass index group.](JAH3-8-e012860-g001){#jah34464-fig-0001}

![Adjusted hazard ratios for NDI‐linked mortality according to body mass index groups. BMI indicates body mass index; NDI, National Death Index.](JAH3-8-e012860-g002){#jah34464-fig-0002}

###### 

Multi‐Variable Cox‐Proportional Hazards Modeling for NDI‐Linked Mortality

                                                  Hazard Ratio   95% CI         *P* Value
  ----------------------------------------------- -------------- -------------- -----------
  eGFR                                                                          
  eGFR \>60 mL/min per 1.73 m^2^                  1 (ref)                       
  eGFR 30 to 60 mL/min per 1.73 m^2^              1.45           1.33 to 1.58   \<0.001
  eGFR \<30 mL/min per 1.73 m^2^                  3.46           3.03 to 3.95   \<0.001
  Cardiogenic shock                               2.98           2.57 to 3.44   \<0.001
  Left ventricular ejection fraction                                            
  Left ventricular ejection fraction \>45%        1 (ref)                       
  Left ventricular ejection fraction 30% to 45%   1.57           1.44 to 1.70   \<0.001
  Left ventricular ejection fraction \<30%        2.50           2.12 to 2.94   \<0.001
  Chronic obstructive airways disease             2.11           1.90 to 2.34   \<0.001
  Out‐of‐hospital cardiac arrest                  1.76           1.47 to 2.10   \<0.001
  BMI category                                                                  
  BMI 18.5 to 24.9 kg/m^2^                        1 (ref)                       
  BMI 25.0 to 29.9 kg/m^2^                        0.85           0.78 to 0.93   \<0.001
  BMI 30.0 to 34.9 kg/m^2^                        0.85           0.76 to 0.94   0.002
  BMI 35.0 to 39.9 kg/m^2^                        0.95           0.80 to 1.12   0.543
  BMI ≥40.0 kg/m^2^                               1.33           1.07 to 1.65   0.010
  Diabetes mellitus                               1.45           1.34 to 1.57   \<0.001
  Peripheral vascular disease                     1.44           1.29 to 1.60   \<0.001
  Obstructive sleep apnea                         1.39           1.19 to 1.63   \<0.001
  Previous coronary artery bypass graft surgery   1.37           1.17 to 1.60   \<0.001
  Previous stroke                                 1.35           1.21 to 1.51   \<0.001
  Left main disease                               1.31           1.04 to 1.64   0.023
  Multivessel disease                             1.25           1.16 to 1.36   \<0.001
  Previous myocardial infarction                  1.19           1.10 to 1.30   \<0.001
  Hypertension                                    1.11           1.01 to 1.22   0.034
  Age (per year increase)                         1.06           1.05 to 1.06   \<0.001
  Drug‐eluting stent use                          0.79           0.73 to 0.85   \<0.001

BMI indicates body mass index; eGFR, estimated glomerular filtration rate; NDI, National Death Index.

Secondary Prevention Therapy {#jah34464-sec-0013}
----------------------------

At 30 days post PCI, there were no significant differences in use of aspirin, a second antiplatelet agent, or statins across the BMI groups (all *P*\>0.05) (Table [5](#jah34464-tbl-0005){ref-type="table"}). However, patients with normal BMI were significantly less likely to receive a β‐blocker or angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker compared with the other BMI groups (*P*=0.003 and *P*\<0.001 respectively).

###### 

Medication Use at 30‐Day Follow‐Up

                                     BMI 18.5 to 24.9 kg/m^2^   BMI 25.0 to 29.9 kg/m^2^   BMI 30.0 to 34.9 kg/m^2^   BMI 35.0 to 39.9 kg/m^2^   BMI ≥40 kg/m^2^   *P* for Trend
  ---------------------------------- -------------------------- -------------------------- -------------------------- -------------------------- ----------------- ---------------
  Aspirin                            5688 (97.7)                9690 (97.4)                5299 (97.6)                1733 (98.1)                758 (96.3)        0.628
  Clopidogrel/prasugrel/ticagrelor   5592 (96.1)                9590 (96.4)                5188 (95.5)                1688 (95.6)                751 (95.6)        0.045
  β‐Blocker                          4494 (77.7)                7827 (79.2)                4295 (80.0)                1410 (80.5)                617 (79.4)        0.003
  ACEi/ARB                           4340 (75.0)                7792 (78.8)                4424 (82.2)                1491 (85.1)                647 (83.3)        \<0.001
  Statin                             5450 (94.2)                9403 (95.1)                5096 (94.5)                1673 (95.3)                747 (95.5)        0.119

Data expressed as numbers (%). ACEi indicates angiotensin‐converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index.

Discussion {#jah34464-sec-0014}
==========

In this large, multicenter study evaluating the relationship between BMI and long‐term mortality in patients undergoing PCI, we observed a J‐shaped association between different BMI groups and adjusted mortality risk, with patients at the extremes of BMI experiencing the highest risk. Although an obesity paradox was present with underweight patients having the highest mortality out of all of the groups, it only extended as far as patients with mild obesity. Therefore, patients with extreme obesity remain at significantly increased risk of long‐term mortality compared with their healthy weight and less obese counterparts.

The results of our study provide important additional insights to the literature regarding outcomes after PCI in patients with varying BMI. Our results are in accordance with several large studies that have demonstrated a similar association between in‐hospital mortality and BMI group.[12](#jah34464-bib-0012){ref-type="ref"}, [17](#jah34464-bib-0017){ref-type="ref"}, [19](#jah34464-bib-0019){ref-type="ref"} A feature of our study is that very few earlier studies have assessed mortality rates beyond 12 months in extremely obese patients undergoing PCI for both stable angina and acute coronary syndromes. Holroyd et al evaluated mortality up to 5 years after PCI in over 300 000 patients and also found that patients who were overweight and obese (BMI \>30 kg/m^2^) had reduced mortality risk up to 5 years compared with those with normal BMI.[16](#jah34464-bib-0016){ref-type="ref"} However, the authors did not further subdivide obese patients further into degrees of obesity, and therefore no conclusions can be made as to whether extreme obesity remains protective. Interestingly, a subgroup analysis on 15 603 patients who underwent PCI and were enrolled in the Canadian APPROACH registry with a median follow‐up of 46 months showed that whereas underweight patients had the highest adjusted mortality risk and moderate obesity was protective, those with extreme obesity had very similar adjusted mortality risk to their normal weight counterparts.[20](#jah34464-bib-0020){ref-type="ref"} It is however difficult to make comparisons with our study to understand reasons behind this difference in outcomes as baseline or procedural characteristics of the PCI subgroup were not presented separately, and medication use data were only available for 12% of the whole cohort (including those not treated with PCI). However, a similar neutral effect of severe obesity (defined as BMI ≥35 kg/m^2^) compared with normal weight on cardiovascular mortality risk after percutaneous or surgical revascularization was also seen in a recent meta‐analysis by Sharma et al, suggesting that further large studies in this area are required.[24](#jah34464-bib-0024){ref-type="ref"}

Several possible mechanisms for the obesity paradox have been postulated. In accordance with previous studies, our data show that there was a linear relationship between BMI and the prevalence of comorbidities such as diabetes mellitus, hypertension, and dyslipidemia. However, patients with higher BMI may be more likely to have been screened earlier and aggressively treated for these cardiovascular risk factors, thereby leading to better long‐term outcomes despite obesity.[25](#jah34464-bib-0025){ref-type="ref"} Overweight and mild‐to‐moderately obese patients were also less likely to present with cardiogenic shock and post--out‐of‐hospital cardiac arrest, factors that are usually associated with poorer outcomes.[26](#jah34464-bib-0026){ref-type="ref"}, [27](#jah34464-bib-0027){ref-type="ref"} Similar to other studies, in‐hospital major bleeding complications were also lower in overweight and obese patients, which is likely at least in part due to the increased use of radial access in these patients.[16](#jah34464-bib-0016){ref-type="ref"} Excess dosing of anticoagulant and antiplatelet drugs is also potentially less likely to occur in more obese patients, which may also reduce their bleeding risk. Bleeding has been shown to be independently associated with worse short‐ and long‐term mortality and therefore may explain our results to some extent.[28](#jah34464-bib-0028){ref-type="ref"}

In our study we also found that increased BMI up to the level of moderate obesity was associated with an increased use of guideline‐based medical therapy, in particular β‐blockers, renin‐angiotensin‐system blockers, and statins. Previous studies have shown that increased use of evidence‐based cardiovascular medications is associated with lower long‐term mortality after PCI.[29](#jah34464-bib-0029){ref-type="ref"} Nonpharmacological measures such as smoking cessation, dietary counseling, and cardiac rehabilitation referral have been shown to be employed more frequently in overweight and obese patients as well, which could also account for the improved outcomes.[30](#jah34464-bib-0030){ref-type="ref"}, [31](#jah34464-bib-0031){ref-type="ref"}

With an increase in the proportion of overweight and obese individuals in the general population as well as in those undergoing PCI, it has also been proposed that the worse prognosis observed in patients with normal BMI may be due to the effect of residual confounding.[17](#jah34464-bib-0017){ref-type="ref"}, [19](#jah34464-bib-0019){ref-type="ref"} Given that 67% of the Australian population are overweight or obese, even having a normal BMI may potentially reflect the presence of unmeasured serious comorbidities that carry substantial mortality hazard.[32](#jah34464-bib-0032){ref-type="ref"} Previous studies have indeed shown that patients with low BMI have higher rates of noncardiac mortality.[33](#jah34464-bib-0033){ref-type="ref"}, [34](#jah34464-bib-0034){ref-type="ref"} In our study we also observed an inverse relationship between BMI and the presence of comorbidities such as chronic obstructive pulmonary disease and peripheral vascular disease. However, we were unable to account for the prevalence of serious conditions such as cancer, dementia, malnutrition, and overall measures of frailty, which could explain the higher mortality in patients even with normal BMI.[35](#jah34464-bib-0035){ref-type="ref"}

Finally, there is also evidence that adipose tissue may itself have potentially cardioprotective effects by producing hormones such as leptin and adiponectin.[36](#jah34464-bib-0036){ref-type="ref"} These hormones have anti‐inflammatory and antiapoptotic properties and might reduce infarct size.[37](#jah34464-bib-0037){ref-type="ref"}, [38](#jah34464-bib-0038){ref-type="ref"} Obesity‐inducing high‐fat diets in rats have also been shown to be cardioprotective.[39](#jah34464-bib-0039){ref-type="ref"} Obesity may also be protective against malnutrition following a major cardiac event or procedure.[40](#jah34464-bib-0040){ref-type="ref"} However, the increase in mortality seen in patients with extreme, class III obesity suggests that there is likely a threshold effect. Therefore, as BMI increases to over 40 kg/m^2^, the protective effects of milder degrees of obesity may be abrogated by the deleterious effects of extreme obesity including alterations in cardiac structure and function, potentiation of an inflammatory and prothrombotic state, and increased noncardiovascular mortality.[41](#jah34464-bib-0041){ref-type="ref"}, [42](#jah34464-bib-0042){ref-type="ref"}, [43](#jah34464-bib-0043){ref-type="ref"} This may explain why the obesity paradox did not extend to the extremely obese in several studies including ours.[17](#jah34464-bib-0017){ref-type="ref"}, [44](#jah34464-bib-0044){ref-type="ref"}

Limitations {#jah34464-sec-0015}
-----------

Our study has several limitations. First, due to the retrospective design of this study, we were unable to account for all potential confounding factors such as socioeconomic status, noncardiac comorbidities such as cancer, as well as measures of frailty, which can all potentially affect post‐PCI short‐ and long‐term mortality. Second, BMI measured at the time of PCI might not necessarily reflect BMI at the time of linkage with the NDI, which was on average 4 years after the index PCI procedure. It is also not known how dynamic weight changes might impact clinical outcomes among patients whose weight had changed between the index PCI and the time of NDI linkage. Third, we did not capture measures of central adiposity such as waist circumference and waist‐to‐hip ratio, which have been shown to be better predictors of cardiovascular outcomes than BMI alone.[45](#jah34464-bib-0045){ref-type="ref"}, [46](#jah34464-bib-0046){ref-type="ref"} However, BMI is the measurement used and endorsed by the World Health Organization to classify obesity worldwide given its simple and easily quantifiable nature, and it was therefore chosen for this study. Finally, we did not have data on the use of guideline‐recommended secondary prevention therapy beyond 30 days after PCI, which might also have explained some of the differences in mortality among BMI groups.[40](#jah34464-bib-0040){ref-type="ref"}

Conclusions {#jah34464-sec-0016}
===========

In conclusion, there remains an obesity paradox with regard to long‐term mortality in patients undergoing PCI in contemporary practice, with mildly obese patients having the lowest adjusted mortality hazard. However, this protective effect does not extend to patients with extreme obesity. Factors behind this phenomenon are likely multifactorial and require further mechanistic and epidemiological studies.
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